Conquering the Undruggable.
Over the coming decade, one prominent category likely to drive substantial changes in drug development and manufacturing is AI.
Coupled with AI, the areas that bring promising potential include age-appropriate and/or personalized therapies, orphan and rare disorders, real world data-driven decisions related to decentralized clinical trials, and enhanced sustainability in both manufacturing and supply chains.
Ideally, drug development in the next decade should be driven by advanced delivery of large molecules, nucleic acids, and drug candidates for so-called “undruggable” targets through novel drug delivery technologies. As AI continues to turbo-charge discovery, development, and manufacturing elements, partnerships with CMOs and CDMOs, for example, will become all the more important in optimizing drug product design, development, and logistics for expedited time to market. Considering the advent and rapid proliferation of AI in drug development – and the need to provide patients with life changing therapies as quickly as possible – augmentation and adaptations to current regulations in areas such as breakthrough, accelerated and fast-track pathways will be necessary.
Regardless, all signs for the next decade point to customization, with drug manufacturing geared toward targeted, niche medicines produced in multi- product facilities offering potent and highly potent drug-handling capabilities, batch production flexibility, therapies and patients. The increased emphasis on
environmental, social and governance issues across various aspects of the pharma sector has been highly encouraging.
The Multifaceted Future of Pharma – Conquering the undruggable with Anshut Gupte | As seen in The Medicine Maker | October 2024
We are committed to supporting clients at every stage of the manufacturing cycle, delivering best-in-class services efficiently and effectively.
Find out more about our Advanced Drug Delivery Solutions.